The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Hollander, E.
* Articles by Smith, T. B.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Hollander, E.
* Articles by Smith, T. B.
Related Collections
* Borderline Personality Disorders
* Symptoms/Dimensions
* Other Violence/Aggression
* Anticonvulsants
Am J Psychiatry 162:621-624, March 2005
© 2005 American Psychiatric Association


Brief Report

Impact of Trait Impulsivity and State Aggression on Divalproex Versus Placebo Response in Borderline Personality Disorder

Eric Hollander, M.D., Alan C. Swann, M.D., Emil F. Coccaro, M.D., Ping Jiang, M.S., and Thomas B. Smith, M.D.

OBJECTIVE: The authors’ goal was to determine whether specific pretreatment clinical characteristics differentially predict favorable treatment response to divalproex versus placebo for impulsive aggression in patients with borderline personality disorder. METHOD: Fifty-two outpatients with DSM-IV borderline personality disorder were randomly assigned to receive divalproex (N=20) or placebo (N=32), double-blind, for 12 weeks. Trait impulsivity symptoms were determined by using the Barratt Impulsiveness Scale, and state aggression symptoms were determined by using the Overt Aggression Scale modified for outpatients. Affective stability was determined by using the Young Mania Rating Scale and the Hamilton Depression Rating Scale. Analyses were performed to identify possible baseline symptom domains that predict treatment response. RESULTS: Divalproex was superior to placebo in reducing impulsive aggression in patients with borderline personality disorder. Divalproex-treated patients responded better than placebo-treated patients among those with higher baseline trait impulsivity symptoms and state aggression symptoms. The effects of baseline trait impulsivity and state aggression appear to be independent of one another. However, baseline affective instability did not influence differential treatment response. CONCLUSIONS: Both pretreatment trait impulsivity symptoms and state aggression symptoms predict a favorable response to divalproex relative to placebo for impulsive aggression in patients with borderline personality disorder.




This article has been cited by other articles:


Home page
J. Neuropsychiatry Clin. Neurosi.Home page
L. A. Miller, R. L. Collins, and T. A. Kent
Language and the Modulation of Impulsive Aggression
J Neuropsychiatry Clin Neurosci, August 1, 2008; 20(3): 261 - 273.
[Abstract] [Full Text] [PDF]


Home page
Int J Offender Ther Comp CriminolHome page
J. Kamath, H. D. Temporini, S. Quarti, Wanli Zhang, K. L. Pagano, N. DeMartinis, and R. L. Trestman
Psychiatric Use and Utility of Divalproex Sodium in Connecticut Prisons
Int J Offender Ther Comp Criminol, June 1, 2008; 52(3): 358 - 370.
[Abstract] [PDF]


Home page
Am. J. PsychiatryHome page
L. J. Siever
Neurobiology of Aggression and Violence
Am J Psychiatry, April 1, 2008; 165(4): 429 - 442.
[Abstract] [Full Text] [PDF]


Home page
CMAJHome page
J. Paris
Borderline personality disorder
Can. Med. Assoc. J., June 7, 2005; 172(12): 1579 - 1583.
[Abstract] [Full Text] [PDF]




Get information about faster international access.

Privacy Policy

Copyright © 2005 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org